Table 4.
Pharmacological treatments given to patients at baseline and at week 26, and intra‐articular glucocorticoid injections and doses given between weeks 0 and 26, by study group
| BASELINE | Week 26 | |||
|---|---|---|---|---|
| Intervention group (n = 29) | Control group (n = 33) | Intervention group (n = 29) | Control group (n = 33) | |
| csDMARD n (%) | 23 (79) | 29 (88) | 24 (83) | 30 (91) |
| MTX n (%) | 23 (79) | 28 (85) | 24 (83) | 30 (91) |
| MTX dose (mg) | 18.9 (4.7) | 18.7 (5.3) | 19.0 (4.6) | 19.5 (4.8) |
| csDMARD, combinations n (%) | 6 (21) | 3 (9) | 6 (21) | 4 (12) |
| bDMARD n (%) | 2 (7) | 9 (27) | 11 (38) | 15 (46) |
| TNFi n (%) | 2 (7) | 9 (27) | 10 (35) | 11 (33) |
| bDMARD, other n (%) | 0 | 0 | 2 (7) | 5 (15) |
| Prednisolone n (%) | 5 (17) | 5 (15) | 4 (14) | 4 (12) |
| Prednisolone dose (mg) | 6.8 (2.4) | 5.5 (2.7) | 7.0 (2.7) | 4.4 (1.3) |
| Weeks 0–26 | ||||
| Intra‐articular glucocorticoids: | ||||
| No. of injections (n/patients) | NA | NA | 8/6 | 6/3 |
| Oral prednisolone courses (n/patients) | 7/6 | 4/4 | ||
| DMARD therapy changes: | ||||
| Changes in csDMARD therapy (n/patients) | NA | NA | 5/5 | 5/5 |
| Changes in bDMARD therapy (n/patients) | NA | NA | 13/13 | 9/9 |
bDMARD: biologic disease‐modifying anti‐rheumatic drug; csDMARD: conventional synthetic disease‐modifying anti‐rheumatic drug; MTX: methotrexate; NA: not applicable; TNFi: tumour necrosis factor inhibitor.